3.69% -1.405

Harrow Inc (HROW)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HROW? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Harrow Inc Stock (HROW) Company Profile

Healthcare (1118)

615.733.4731

1A BURTON HILLS BLVD, NASHVILLE, CA

Nächster Verdiensttermin

Neueste SEC-Einreichungen

HROW's Discussions on Twitter

Compare HROW vs TAK, ZTS, HLN, TEVA, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HROW Harrow Inc	34.09	1.32B	272.30M	-5.14M	42.76M	-0.1635
TAK Takeda Pharmaceutical Co Adr	17.82	56.14B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	114.85	48.74B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.06	44.85B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	28.83	34.12B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	536.15	23.35B	3.13B	1.27B	1.12B	26.39

Harrow Inc Stock (HROW) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-11	Eingeleitet	Cantor Fitzgerald	Overweight
2025-06-12	Eingeleitet	BTIG Research	Buy
2025-06-10	Eingeleitet	William Blair	Outperform
2025-02-06	Eingeleitet	H.C. Wainwright	Buy
2024-12-04	Bestätigt	B. Riley Securities	Buy
2024-04-11	Eingeleitet	Craig Hallum	Buy
2022-09-08	Fortgesetzt	B. Riley Securities	Buy
2021-10-14	Fortgesetzt	B. Riley Securities	Buy
2021-09-24	Eingeleitet	Aegis Capital	Buy
2021-07-02	Eingeleitet	Ladenburg Thalmann	Buy

Alle ansehen

Harrow Inc Aktie (HROW) Neueste Nachrichten

Finanzdaten der Harrow Inc-Aktie (HROW)

Harrow Inc (HROW)

Harrow Inc Stock (HROW) Company Profile

Compare HROW vs TAK, ZTS, HLN, TEVA, UTHR

Harrow Inc Stock (HROW) Upgrades & Downgrades

Harrow Inc Aktie (HROW) Neueste Nachrichten

Why Harrow (HROW) Is Down 6.5% After Raising 2026 Guidance And Advancing TRIESENCE To Phase 3 - simplywall.st

Harrow Health at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com

Harrow (HROW) Q4 2025 Earnings Call Transcript - AOL.com

HROW: Record growth and expanding ophthalmic portfolio drive optimism for future launches - TradingView

Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions - Investing.com Canada

Harrow Health Projects Robust Growth After Strong 2025 - TipRanks

Is Harrow Inc. stock a top pick in earnings seasonTrade Performance Summary & Safe Entry Point Alerts - Naître et grandir

Has The Recent Slide In Harrow (HROW) Opened A Valuation Opportunity For Investors - simplywall.st

HC Wainwright Issues Negative Forecast for Harrow Earnings - MarketBeat

HROWHarrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits - mx.advfn.com

Buy or Sell Harrow Stock? - Trefis

A Look At Harrow (HROW) Valuation After Mixed Q4 Results And 2026 Profitability Concerns - Yahoo Finance

A Look At Harrow (HROW) Valuation After Q4 2025 Earnings Miss And Raised 2026 Spending Plans - simplywall.st

HC Wainwright Has Pessimistic Outlook of Harrow Q3 Earnings - MarketBeat

Harrow (NASDAQ:HROW) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat

Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference - The Globe and Mail

H.C. Wainwright raises Harrow Health stock price target to $70 By Investing.com - Investing.com UK

Harrow stock stabilizes after major Tuesday drop - Nashville Post

Harrow Inc (HROW) Trading 4.78% Higher on Mar 4 - GuruFocus

Cantor Fitzgerald lowers Harrow Health stock price target to $91 - Investing.com

Cantor Fitzgerald Lowers Harrow (NASDAQ:HROW) Price Target to $91.00 - MarketBeat

These Analysts Revise Their Forecasts On Harrow Following Q4 Results - Benzinga

Harrow (HROW): Today's Analyst Rating and Price Target Update | - GuruFocus

Harrow (NASDAQ:HROW) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Harrow Health, Inc. (NASDAQ:HROW) Q4 2025 Earnings Call Transcript - Insider Monkey

HROW: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus

Does Harrow’s (HROW) TRIESENCE Cataract Trial Redefine Its Dropless Eye Care Strategy? - simplywall.st

H.C. Wainwright raises Harrow Health stock price target to $70 - Investing.com

Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade) (NASDAQ:HROW) - Seeking Alpha

Harrow (HROW) -28%: 2026 Guidance Disappoints Market - Trefis

Would You Still Hold Harrow Stock If It Fell Another 30%? - Trefis

With Harrow Stock Sliding, Have You Assessed The Risk? - Trefis

Harrow 2026 slides: ophthalmic firm targets $357M revenue amid stock decline - Investing.com

Harrow (HROW) Projects Strong Growth with Expanding Ophthalmic P - GuruFocus

Opaleye-managed account sells Harrow (HROW) shares at $54.18 in Form 4 - Stock Titan

William Blair reiterates Harrow Health stock rating on ophthalmic growth - Investing.com

Harrow Shares Collapse, Another Opportunity? (NASDAQ:HROW) - Seeking Alpha

Notable Two Hundred Day Moving Average CrossHROW - Nasdaq

Why Is Eye-Disease-Focused Harrow Stock Falling Today? (UPDATED) - Benzinga

Harrow Q4 Earnings Call Highlights - MarketBeat

Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm

Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss - MarketBeat

HROW: 2025 revenue grew 36% with strong momentum and 2026 guidance set at $350M–$365M - TradingView

HROW: Strong 2025 growth and expanded sales force set the stage for accelerated 2026 revenue - TradingView

Harrow Stock Falls 21% After FDA Clears IND Application For Phase 3 Trial Of TRIESENCE - Nasdaq

Harrow Health, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

HROW Gains FDA Approval for Phase 3 Trial of Triesence - GuruFocus

Harrow, Inc. (HROW) Stock Analysis: A 31.79% Upside in the Healthcare Sector Beckons Investors - DirectorsTalk Interviews

HROW: 2025 delivered robust revenue and EBITDA growth, with 2026 set for further expansion - TradingView

Eye drug TRIESENCE moves into Phase 3 test to ease cataract surgery recovery - Stock Titan

Finanzdaten der Harrow Inc-Aktie (HROW)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie HROW